New imaging probe could revolutionize cancer diagnosis
NCT ID NCT06977945
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study tests a new imaging agent called FL-091, which targets a protein (NTSR1) found on many cancer cells. By attaching a radioactive label, doctors can see tumors more clearly on PET or SPECT scans. The goal is to improve early diagnosis and staging of cancers like head and neck, colorectal, and pancreatic cancer. About 100 adults with suspected or confirmed NTSR1-positive tumors will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS WITH POSITIVE NTSR1 EXPRESSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital,China
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.